Current topics in medicinal chemistry · 2026
A Comprehensive Review of Chalcones in Dual-Targeted Therapeutics for the Treatment of Parkinson's Disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dhinakaran Keerthana, Sivaperuman Amuthalakshmi, Natarajan Ramalakshmi, Kesavan Yuvarani, Nagarajan Nalini Calambur, Solomon Viswas Raja
Аннотация
INTRODUCTION: The design of novel therapeutic entities for neurodegenerative diseases, particularly Parkinson's disease, remains a major challenge in medicinal chemistry. Current treatment strategies primarily rely on symptomatic management, often involving levodopa in combination with catechol-O-methyltransferase (COMT) inhibitors to prolong its therapeutic effect. However, these approaches do not adequately address the multifactorial nature of the disease. This study aims to explore the potential of chalcone derivatives as dual-target-directed ligands capable of modulating both COMT and adenosine A₂A receptors for improved therapeutic outcomes in Parkinson's disease.
METHODS: A comprehensive analysis of chalcone-based scaffolds, particularly those incorporating heterocyclic moieties, was undertaken to evaluate their suitability as multitarget agents. Emphasis was placed on their structural versatility and ability to interact with key biological targets involved in Parkinson's disease pathology.
RESULTS: Chalcones exhibit promising pharmacological properties, including the ability to inhibit COMT, thereby reducing levodopa metabolism, and antagonize adenosine A₂A receptors, which play a crucial role in regulating neurotransmission and motor function.
DISCUSSION: The incorporation of heterocyclic substituents appears to enhance target affinity and selectivity, likely through improved molecular interactions within the binding site. Furthermore, the observed multitarget activity may confer synergistic therapeutic benefits by concurrently modulating multiple pathological pathways, which is particularly advantageous for the treatment of complex multifactorial diseases.
CONCLUSION: Chalcone derivatives represent a promising class of multitarget compounds for Parkinson's disease management. Their dual inhibitory activity against COMT and A₂A receptors, combined with their structural flexibility, supports their potential for further development as effective neuroprotective agents.
METHODS: A comprehensive analysis of chalcone-based scaffolds, particularly those incorporating heterocyclic moieties, was undertaken to evaluate their suitability as multitarget agents. Emphasis was placed on their structural versatility and ability to interact with key biological targets involved in Parkinson's disease pathology.
RESULTS: Chalcones exhibit promising pharmacological properties, including the ability to inhibit COMT, thereby reducing levodopa metabolism, and antagonize adenosine A₂A receptors, which play a crucial role in regulating neurotransmission and motor function.
DISCUSSION: The incorporation of heterocyclic substituents appears to enhance target affinity and selectivity, likely through improved molecular interactions within the binding site. Furthermore, the observed multitarget activity may confer synergistic therapeutic benefits by concurrently modulating multiple pathological pathways, which is particularly advantageous for the treatment of complex multifactorial diseases.
CONCLUSION: Chalcone derivatives represent a promising class of multitarget compounds for Parkinson's disease management. Their dual inhibitory activity against COMT and A₂A receptors, combined with their structural flexibility, supports their potential for further development as effective neuroprotective agents.